Drugs / JNJ-55920839
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02609789 | Dec 2015 → Sep 2018 | systemic lupus erythematosus | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-55920839 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02609789 ↗ |
| Action | Inhibit | “selectively neutralises most human IFNα subtypes and IFNω” PMID 38273624 ↗ Aug 2020 |
| Modality | Monoclonal antibody | “a human monoclonal antibody that selectively neutralises most human IFNα subtypes and IFNω” PMID 38273624 ↗ Aug 2020 |
| Route | Subcutaneous | “a single subcutaneous dose” NCT02609789 ↗ |